They really must be handicapped by the fda, or the fact that it’s from compassionate use and not a trial. Clearly he’s being restrained as evidenced by lack of details but also by his use of the word “anecdotal” every time he speaks about results now. It also may be something as simple as wanting the last two patient’s information before putting it all out there with more explanation of the impact Leronlimab has had. Maybe that’s what he’s holding back for tomorrow. I’m with you though, and was really hoping there’d be some strong wording around the patient recovery/results. It would have made it a lot easier for the common investor to get excited if it were more descriptive. Not everyone will add things up the way those of us who follow it daily will be able to. Still good, just was hoping for better.